Fipco
@fipco.bsky.social
According to clinicaltrials.gov the baricitinib CV safety trials completed 6 months ago. Perhaps more t's to cross and i's to dot. This EULAR consensus review pointed to these studies as important in assessing JAKi safety. pubmed.ncbi.nlm.nih.gov/36357155/
bsky.app/profile/fipc...
bsky.app/profile/fipc...
November 30, 2025 at 6:48 PM
According to clinicaltrials.gov the baricitinib CV safety trials completed 6 months ago. Perhaps more t's to cross and i's to dot. This EULAR consensus review pointed to these studies as important in assessing JAKi safety. pubmed.ncbi.nlm.nih.gov/36357155/
bsky.app/profile/fipc...
bsky.app/profile/fipc...
The Economist on apoB. ApoB is inexpensive and more accurate than LDL-C. The measures disagree in 30-40% of individuals. www.economist.com/science-and-... #cardiosky
November 26, 2025 at 1:25 PM
The Economist on apoB. ApoB is inexpensive and more accurate than LDL-C. The measures disagree in 30-40% of individuals. www.economist.com/science-and-... #cardiosky
Probably yes, for example lixisenatide - short half-life GLP-1ra dosed once a day was not superior to placebo on MACE (ELIXA). Real world data has some value, but results are all over the place. IMO CVOTs suggest both semaglutide and tirzepatide are good options for secondary prevention.
September 18, 2025 at 3:03 PM
Probably yes, for example lixisenatide - short half-life GLP-1ra dosed once a day was not superior to placebo on MACE (ELIXA). Real world data has some value, but results are all over the place. IMO CVOTs suggest both semaglutide and tirzepatide are good options for secondary prevention.
• start prevention earlier (than current guidelines suggest)
• measure apoB
Editorial by Angela Pirillo and Alberico Catapano #cardiosky
academic.oup.com/eurheartj/ad...
• measure apoB
Editorial by Angela Pirillo and Alberico Catapano #cardiosky
academic.oup.com/eurheartj/ad...
September 9, 2025 at 9:44 PM
• start prevention earlier (than current guidelines suggest)
• measure apoB
Editorial by Angela Pirillo and Alberico Catapano #cardiosky
academic.oup.com/eurheartj/ad...
• measure apoB
Editorial by Angela Pirillo and Alberico Catapano #cardiosky
academic.oup.com/eurheartj/ad...
ICER organization draft: Semaglutide and tirzepatide for obesity are cost effective. For context, a 2014 ACC/AHA task force suggested a less than $50k per QALY threshold as "high value". #cardiosky icer.org/assessment/o...
September 9, 2025 at 6:14 PM
ICER organization draft: Semaglutide and tirzepatide for obesity are cost effective. For context, a 2014 ACC/AHA task force suggested a less than $50k per QALY threshold as "high value". #cardiosky icer.org/assessment/o...
Key take home: current risk models understate clinical & economic benefit of long term bp/lipid lowering.
Link to slides corserahealth.com/assets/pdfs/...
Link to slides corserahealth.com/assets/pdfs/...
September 8, 2025 at 1:19 PM
Key take home: current risk models understate clinical & economic benefit of long term bp/lipid lowering.
Link to slides corserahealth.com/assets/pdfs/...
Link to slides corserahealth.com/assets/pdfs/...
NATURE-Legacy study compares MR/genetically modeled life long LDL-C and blood pressure lowering (HR 0.32) to short term effects in the HOPE-3 trial (HR 0.71). By Brian Ference, et al. /1 #ESCCongress2025 #cardiosky
September 8, 2025 at 1:19 PM
NATURE-Legacy study compares MR/genetically modeled life long LDL-C and blood pressure lowering (HR 0.32) to short term effects in the HOPE-3 trial (HR 0.71). By Brian Ference, et al. /1 #ESCCongress2025 #cardiosky
Statin eligibility with PREVENT vs PCE 10 year risk at various thresholds by Sadiya Kahn, et al.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
August 21, 2025 at 1:02 AM
Statin eligibility with PREVENT vs PCE 10 year risk at various thresholds by Sadiya Kahn, et al.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
On the surface, in this dataset of 240k, the PCE calibration seems closer to actual than PREVENT. Excerpt S-Table 45.
bsky.app/profile/pnat...
bsky.app/profile/pnat...
July 14, 2025 at 5:57 PM
On the surface, in this dataset of 240k, the PCE calibration seems closer to actual than PREVENT. Excerpt S-Table 45.
bsky.app/profile/pnat...
bsky.app/profile/pnat...
In Norway🇳🇴, 4 years after DAPA-HF, 85% of those with reduced ejection fraction heart failure get an SGLT2i. In the US🇺🇸, it's under 30%. #gdmt #flozins #cardiosky
www.hcplive.com/view/study-h...
onlinelibrary.wiley.com/doi/10.1002/...
www.hcplive.com/view/study-h...
onlinelibrary.wiley.com/doi/10.1002/...
July 11, 2025 at 3:43 PM
In Norway🇳🇴, 4 years after DAPA-HF, 85% of those with reduced ejection fraction heart failure get an SGLT2i. In the US🇺🇸, it's under 30%. #gdmt #flozins #cardiosky
www.hcplive.com/view/study-h...
onlinelibrary.wiley.com/doi/10.1002/...
www.hcplive.com/view/study-h...
onlinelibrary.wiley.com/doi/10.1002/...
Systemic review of discordance studies by Daniel Sehayek, et al. finds apoB generally outperforms LDL-C and non-HDL-C. (prior post of recent study adds to this evidence) #cardiosky
www.lipidjournal.com/article/S193...
www.lipidjournal.com/article/S193...
June 11, 2025 at 1:19 AM
Systemic review of discordance studies by Daniel Sehayek, et al. finds apoB generally outperforms LDL-C and non-HDL-C. (prior post of recent study adds to this evidence) #cardiosky
www.lipidjournal.com/article/S193...
www.lipidjournal.com/article/S193...
Converting mean apoB and LDL-C values to population percentiles (using NHANES) shows risk tracks with apoB. (ASCVD % from Figure 1) Results similar for non-HDL-C. /2-fin
June 11, 2025 at 1:03 AM
Converting mean apoB and LDL-C values to population percentiles (using NHANES) shows risk tracks with apoB. (ASCVD % from Figure 1) Results similar for non-HDL-C. /2-fin
Mid-sized 🇬🇷discordance study (n=3042, 20 year follow-up) favors apoB over traditional lipid measures. By Giannakopoulou et al. /1 #cardiosky pubmed.ncbi.nlm.nih.gov/40386959/
June 11, 2025 at 1:03 AM
Mid-sized 🇬🇷discordance study (n=3042, 20 year follow-up) favors apoB over traditional lipid measures. By Giannakopoulou et al. /1 #cardiosky pubmed.ncbi.nlm.nih.gov/40386959/
Related editorial by Sniderman et al. #apoB #Lp(a) #cardiosky academic.oup.com/eurheartj/ad...
bsky.app/profile/eric...
bsky.app/profile/eric...
May 13, 2025 at 4:50 PM
Related editorial by Sniderman et al. #apoB #Lp(a) #cardiosky academic.oup.com/eurheartj/ad...
bsky.app/profile/eric...
bsky.app/profile/eric...
Soap opera of KETO-CTA study continues. Revision of paper expected per last author Budoff.
Another cohort NATURE-CT with similar demographics - age, no statin - had ~1/4 the non-calcified plaque progression of the keto group 4.9 v 18.8.
bsky.app/profile/fipc...
Another cohort NATURE-CT with similar demographics - age, no statin - had ~1/4 the non-calcified plaque progression of the keto group 4.9 v 18.8.
bsky.app/profile/fipc...
April 19, 2025 at 2:42 AM
Soap opera of KETO-CTA study continues. Revision of paper expected per last author Budoff.
Another cohort NATURE-CT with similar demographics - age, no statin - had ~1/4 the non-calcified plaque progression of the keto group 4.9 v 18.8.
bsky.app/profile/fipc...
Another cohort NATURE-CT with similar demographics - age, no statin - had ~1/4 the non-calcified plaque progression of the keto group 4.9 v 18.8.
bsky.app/profile/fipc...
"majority [had] minimal progression"- co-author of KETO-CTA study. The values in Figure 1 for non-calcified plaque imply a 50% increase in median at 1 year. Big ⬆️'s in many w/ CAC=0. Nakanishi paper suggests annual increase in non-diabetics of 2.8 mm^3. bsky.app/profile/shoa...
April 12, 2025 at 6:52 PM
"majority [had] minimal progression"- co-author of KETO-CTA study. The values in Figure 1 for non-calcified plaque imply a 50% increase in median at 1 year. Big ⬆️'s in many w/ CAC=0. Nakanishi paper suggests annual increase in non-diabetics of 2.8 mm^3. bsky.app/profile/shoa...
Age at which CAC becomes detectable in young adults by sex, race, and risk factors (based on CARDIA & CAC Consortium) by Yvette Yeboah-Kordieh et al. Potential paradigm for early prevention. #cardiosky
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
March 5, 2025 at 12:56 AM
Age at which CAC becomes detectable in young adults by sex, race, and risk factors (based on CARDIA & CAC Consortium) by Yvette Yeboah-Kordieh et al. Potential paradigm for early prevention. #cardiosky
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
Update: Novartis now guides to 2026 readout for event driven trial Lp(a)HORIZON. clinicaltrials.gov still lists 1º completion May '25. bsky.app/profile/fipc...
January 31, 2025 at 10:50 AM
Update: Novartis now guides to 2026 readout for event driven trial Lp(a)HORIZON. clinicaltrials.gov still lists 1º completion May '25. bsky.app/profile/fipc...
After recent colchicine disappointments, a cautious review of inflammation targeting for CV disease by Kevin Williams. h/t Pablo Corral.. Similar skepticism from @kaulcsmc.bsky.social
pubmed.ncbi.nlm.nih.gov/39846349/
#cardiosky /1
pubmed.ncbi.nlm.nih.gov/39846349/
#cardiosky /1
January 26, 2025 at 3:36 PM
After recent colchicine disappointments, a cautious review of inflammation targeting for CV disease by Kevin Williams. h/t Pablo Corral.. Similar skepticism from @kaulcsmc.bsky.social
pubmed.ncbi.nlm.nih.gov/39846349/
#cardiosky /1
pubmed.ncbi.nlm.nih.gov/39846349/
#cardiosky /1
44 year history of Danish mortality and CHD for individuals with and without familial hypercholesterolemia (FH). In late 1970's (pre-statins), mean age of death was 50 for those with FH, compared to 72 years for those without. #cardiosky h/t Borge Nordestgaard academic.oup.com/eurheartj/ad...
January 18, 2025 at 3:58 PM
44 year history of Danish mortality and CHD for individuals with and without familial hypercholesterolemia (FH). In late 1970's (pre-statins), mean age of death was 50 for those with FH, compared to 72 years for those without. #cardiosky h/t Borge Nordestgaard academic.oup.com/eurheartj/ad...
Reminder: smaller, shorter duration phase 3 lipid lowering trials can give imprecise point estimates for MACE reduction. Alirocumab in ODYSSEY LONG TERM had a MACE+ hazard ratio of 0.52. The larger ODYSSEY OUTCOMES hazard ratio (2.8y median follow-up) was 0.85. #cardiosky
December 10, 2024 at 3:29 PM
Reminder: smaller, shorter duration phase 3 lipid lowering trials can give imprecise point estimates for MACE reduction. Alirocumab in ODYSSEY LONG TERM had a MACE+ hazard ratio of 0.52. The larger ODYSSEY OUTCOMES hazard ratio (2.8y median follow-up) was 0.85. #cardiosky
For the price of a Baltimore Orioles ticket, you can test the Lp(a) of 4 people. (with rates negotiated by insurers with large labs) Link to CMS zip file
www.cms.gov/Medicare/Med...
www.cms.gov/Medicare/Med...
November 24, 2024 at 10:24 PM
For the price of a Baltimore Orioles ticket, you can test the Lp(a) of 4 people. (with rates negotiated by insurers with large labs) Link to CMS zip file
www.cms.gov/Medicare/Med...
www.cms.gov/Medicare/Med...
Vumedi.com has a replay of ASPC's August Lp(a) debate w/ Vera Bittner & @rblument1.bsky.social Note: typical cost of test much lower than they say. Medicare collected every private payment for this & other dx tests between Jan-Jun 2016. There were ~78k Lp(a) tests, weighted median price ~$14.
November 24, 2024 at 10:24 PM
Vumedi.com has a replay of ASPC's August Lp(a) debate w/ Vera Bittner & @rblument1.bsky.social Note: typical cost of test much lower than they say. Medicare collected every private payment for this & other dx tests between Jan-Jun 2016. There were ~78k Lp(a) tests, weighted median price ~$14.
Probably need a large absolute Lp(a) reduction to move the needle.
November 20, 2024 at 9:15 PM
Probably need a large absolute Lp(a) reduction to move the needle.